StockData
Vaxart, Inc. logo

Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –

Vaxart revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Vaxart's revenue for the twelve months ending Jun 30, 2026 was $243.06M, up 201.1% year over year. For fiscal 2025 it was $237.26M, up 726.7% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $237.26M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$237.26M+726.7%
FY2024Dec 31, 2024$28.70M+288.9%
FY2023Dec 31, 2023$7.38M+6796.3%
FY2022Dec 31, 2022$107.00K-88.0%
FY2021Dec 31, 2021$892.00K-78.0%
FY2020Dec 31, 2020$4.05M-59.0%
FY2019Dec 31, 2019$9.86M+137.1%
FY2018Dec 31, 2018$4.16M-55.3%
FY2016Jun 30, 2016$9.30M-62.2%
FY2015Jun 30, 2015$24.60M-64.2%
FY2014Jun 30, 2014$68.70M+104.5%
FY2013Jun 30, 2013$33.60M+64.7%
FY2012Jun 30, 2012$20.40M+94.5%
FY2009Dec 26, 2009$10.49M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$27.19M-31.6%
Q1 FY2026CQ1 2026Mar 31, 2026$39.23M+87.9%
Q4 FY2025CQ4 2025Dec 31, 2025$104.24M+586.5%
Q3 FY2025CQ3 2025Sep 30, 2025$72.41M+1367.9%
Q2 FY2025CQ2 2025Jun 30, 2025$39.73M+520.7%
Q1 FY2025CQ1 2025Mar 31, 2025$20.88M+857.2%
Q4 FY2024CQ4 2024Dec 31, 2024$15.19M+368.0%
Q3 FY2024CQ3 2024Sep 30, 2024$4.93M+134.8%
Q2 FY2024CQ2 2024Jun 30, 2024$6.40M+371.4%
Q1 FY2024CQ1 2024Mar 31, 2024$2.18M+223.1%
Q4 FY2023CQ4 2023Dec 31, 2023$3.25M+14650.0%
Q3 FY2023CQ3 2023Sep 30, 2023$2.10M–
Q2 FY2023CQ2 2023Jun 30, 2023$1.36M–
Q1 FY2023CQ1 2023Mar 31, 2023$675.00K+694.1%
Q4 FY2022CQ4 2022Dec 31, 2022$22.00K-70.3%
Q3 FY2022CQ3 2022Sep 30, 2022$0-100.0%
Q2 FY2022CQ2 2022Jun 30, 2022$0-100.0%
Q1 FY2022CQ1 2022Mar 31, 2022$85.00K-83.2%
Q4 FY2021CQ4 2021Dec 31, 2021$74.00K-79.2%
Q3 FY2021CQ3 2021Sep 30, 2021$200.00K-24.5%
Q2 FY2021CQ2 2021Jun 30, 2021$112.00K-78.6%
Q1 FY2021CQ1 2021Mar 31, 2021$506.00K-82.6%
Q4 FY2020CQ4 2020Dec 31, 2020$356.00K-90.9%
Q3 FY2020CQ3 2020Sep 30, 2020$265.00K-41.6%
Q2 FY2020CQ2 2020Jun 30, 2020$523.00K+515.3%
Q1 FY2020CQ1 2020Mar 31, 2020$2.90M-46.3%
Q4 FY2019CQ4 2019Dec 31, 2019$3.92M+121.6%
Q3 FY2019CQ3 2019Sep 30, 2019$454.00K+61.6%
Q2 FY2019CQ2 2019Jun 30, 2019$85.00K-86.0%
Q1 FY2019CQ1 2019Mar 31, 2019$5.41M+259.7%
Q4 FY2018CQ4 2018Dec 31, 2018$1.77M+194.5%
Q3 FY2018CQ3 2018Sep 30, 2018$281.00K-94.7%
Q2 FY2018CQ2 2018Jun 30, 2018$608.00K-64.2%
Q1 FY2018CQ1 2018Mar 31, 2018$1.50M-11.6%
Q4 FY2016CQ2 2016Jun 30, 2016$600.00K-85.4%
Q3 FY2016CQ1 2016Mar 31, 2016$5.30M-10.2%
Q2 FY2016CQ4 2015Dec 31, 2015$1.70M–
Q1 FY2016CQ3 2015Sep 30, 2015$1.70M–
Q4 FY2015CQ2 2015Jun 30, 2015$4.10M–
Q3 FY2015CQ1 2015Mar 31, 2015$5.90M–

More Vaxart figures

See a number that looks wrong?